Teva Pharmaceutical Business Process Managment

TEVA Pharmaceutical

Company Overview

• Teva Pharmaceutical Industries Ltd is a global pharmaceutical company specializing in the development, production and marketing of generic^[1] and branded pharmaceuticals as well as active pharmaceutical ingredients.
• The company head quarter at Israel, the company total sales count for US $ 13.9 Billion in 2009 with growth exceed 25%; North America and Europe sales represent 80% of company sales. 35’000 employees are working for Teva and the company has production facilities in Israel, North America, Europe and Latin America.
• Teva is ranked 15 among different pharmaceutical companies and considered the largest generic pharmaceutical company in the world.

TEVA main activities:

The company scope of activities includes manufacturing and marketing of products in the following categories:

1. Human pharmaceuticals, Teva produces generic drugs in all major therapeutics areas and in different dosages forms, sterile, tablets and capsules, ointments, creams and liquids.
2. Active Pharmaceutical Ingredients (API), Teva is a leading global supplier of Active Pharmaceutical Ingredients, Teva distribute its APIs to different manufacturing facilities and pharmaceutical manufacturers worldwide, this represent one of the core activities that account for 90% of Teva total sales.

TEVA Partnership and intellectual property:

• Teva intellectual property has been built by partnership with different institution and small companies, and this allow Teva to have more than 3600 registered and patent records, 90% of submitted patents had being granted. Teva offer smaller companies and academic institutions access to resources, and strive to be partner of choice, they create a win-win situation for both Teva and their partners.

• Since the beginning of 2010, Teva has received 206 generic approvals in Europe relating to 64 compounds in 135 formulations, including three EMA (European Medicines Agency) approvals valid in all EU member states. In addition, as of March 31, 2010, Teva had approximately 3,207 marketing authorization applications pending approval in 30 European countries, relating to 242 compounds in 474 formulations, including six applications pending with the EMA.
• Teva had 210 product applications awaiting final FDA approval.

Expansion through Acquisitions:

• Teva ‘went through the European markets via acquisitions , it’s start with the Dutch company Pharmachemie B.V then GRY-Pharm, APS/Berk , Biogal and others. Through these acquisitions, Teva has successfully established a network of subsidiaries across Europe.
• In the year 2000, Teva's acquired Novopharm in Canada.
• In 2002 of Teva acquired Bayer in France and Honeywell Fine Pharmaceutical Chemical plants in northern Italy.
• On January 22, 2004, Teva acquired Sicor Pharmaceuticals.
• In 2006, Teva acquired IVAX which expanded product lines in generics.
• In December 2008, Teva has completed its acquisition of Barr Pharmaceuticals in the US and its European subsidiary Pliva.
• In 2010 Teva has an agreement to acquire ratiopharm, an important milestone , that  will make Teva - the global generics leader and –“ the leader in Europe as well."

Stock Market:

Teva is trade its shares on the Tel Aviv Stock Exchange and also traded on Seaq International in London and the Frankfurt Stock Exchange.

Key financial figures:

Quarterly net sales of $3.7 billion, up 16%, compared to the comparable period in 2009.